Trinity Capital Inc Aktie News

PHOENIX , Oct. 23, 2025 /PRNewswire/ --  Trinity Capital Inc.  (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the funding of equipment and other asset financing to Bobbie, the mom-founded and led organic infant feeding company. Bobbie is known for its American-manufactured, organic, European-style infant formulas designed with simple, high-quality ingredien...

Thirteen of 35 October Dividend Power Dogs are recommended for their "safer" dividends, with free cash-flow yields exceeding dividend yields, making them ideal buys. The Dividend Power strategy focuses on high earnings yield and high dividend yield, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for the top ten DiviPower stocks by October ...

PHOENIX , Oct. 21, 2025 /PRNewswire/ --  Trinity Capital Inc.  (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to Kard Financial, Inc., ("Kard"), a commerce media network that helps fintechs and financial institutions drive usage, loyalty, and engagement through merchant-specific rewards. Kard powers next-gener...

Many investors have become fearful of BDCs. The sector wide 22% discount to NAV is proof of that. Yet, very recently I have been adding more to my positions.

The American Dream is embodied by millions of small and mid-sized businesses. BDCs support middle-market companies by providing credit and growth capital. We discuss ways to generate great income from BDCs, which support America's backbone of businesses.

Business development companies (BDCs) are selling off. Recent bankruptcies are sparking fears across private credit. I review the best BDC opportunities following the sell-off.

PHOENIX , Oct. 14, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $130 million in growth capital to Candel Therapeutics, Inc. (Nasdaq: CADL) ("Candel"), a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer. Candel Therapeutics is devel...

Trinity Capital Inc. remains a Buy despite the recent BDC sector selloff, supported by strong fundamentals, consistent dividends, and record NAV growth. Trinity Capital reported Q2 2025 investment income up 27%, NII up 30%, and NAV up 36% year-over-year, with low non-accruals and robust portfolio diversification. Fears of lower interest rates are overblown for TRIN, as its funding costs would f...